Related Experiment Videos
Cyclosporin, nifedipine and gingival hyperplasia: a randomized controlled study
J D Morgan1, M J Swarbrick, C M Edwards
1Department of Surgery, Leicester General Hospital, UK.
Summary
Nifedipine worsens gingival hyperplasia in renal transplant patients on cyclosporine (CyA) therapy, independent of CyA blood levels. Strict oral hygiene and prompt surgical referral are crucial for managing this side effect and preventing potential malignancies.
Area of Science:
- Nephrology
- Pharmacology
- Oncology
Background:
- Renal transplant recipients often require immunosuppression with cyclosporine (CyA).
- Gingival hyperplasia is a known side effect of CyA therapy.
- Nifedipine is a commonly prescribed calcium channel blocker.
Purpose of the Study:
- To investigate the effect of nifedipine on CyA-induced gingival hyperplasia in renal transplant recipients.
- To assess the relationship between nifedipine, CyA levels, and gingival hyperplasia severity.
Main Methods:
- Observational study of renal transplant recipients on CyA therapy.
- Evaluation of gingival hyperplasia incidence and severity in patients receiving nifedipine concurrently.
- Correlation analysis with whole-blood CyA levels.
Main Results:
- Nifedipine significantly increases the frequency and severity of gingival hyperplasia in patients on CyA.
- This effect is independent of whole-blood CyA concentrations.
- De novo malignancies have been reported in hyperplastic gingival tissue in this patient group.
Conclusions:
- Concomitant use of nifedipine and CyA exacerbates gingival hyperplasia.
- Patients require counseling on meticulous oral hygiene to mitigate hyperplasia.
- Severe cases necessitate gingivectomy and histological examination due to malignancy risk.